Freshpet (FRPT)
(Delayed Data from NSDQ)
$132.24 USD
+1.73 (1.33%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $132.21 -0.03 (-0.02%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$132.24 USD
+1.73 (1.33%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $132.21 -0.03 (-0.02%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum B VGM
Zacks News
Medifast (MED) Tumbles 25% in 3 Months: Should You Buy Now?
by Zacks Equity Research
Medifast (MED) is encountering difficulties in attracting customers due to a reduction in the number of active OPTAVIA Coaches and diminished productivity per Coach.
General Mills (GIS) Hurt by Volatile Consumer Trends, Cost Woes
by Zacks Equity Research
While brand strength and the Accelerate strategy aid General Mills (GIS), the challenging operating environment and cost-related hurdles keep the near term under pressure.
Newell (NWL) Stock Declines 22% in 3 Months: Can it Rebound?
by Zacks Equity Research
Newell (NWL) is battling uncertainties like a tough macroeconomic environment and elevated levels of core inflation, leading to soft discretionary demand and soft sales
Lamb Weston (LW) Down More Than 40% in 6 Months: Here's Why
by Zacks Equity Research
Lamb Weston (LW) is battling key issues like ongoing input cost inflation, persistent execution difficulties and a softening in global demand for frozen fries.
McCormick's (MKC) Solid Brands & Cost Savings Propel Growth
by Zacks Equity Research
McCormick's (MKC) commitment to achieving long-term objectives is evident from its proven track record and wide-reaching and competitive global portfolio with a focus on high-growth areas.
Conagra Brands (CAG) Fuels Portfolio With Sweetwood Smoke Buyout
by Zacks Equity Research
Conagra Brands' (CAG) acquisition of Sweetwood Smoke & Co. highlights its focus on expanding in the innovative, high-protein snacks category.
Freshpet (FRPT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Freshpet (FRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Monster Beverage (MNST) Stock Down on Q2 Earnings & Sales Miss
by Zacks Equity Research
Monster Beverage (MNST) posts soft second-quarter 2024 results. Its Monster Energy Drinks segment's sales rise 3.3% year over year.
Pre-Markets Deep in Red, Sell-off in Global Markets Intensifies
by Zacks Equity Research
Pre-Markets Deep in Red, Sell-off in Global Markets Intensifies.
Freshpet (FRPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Freshpet (FRPT) delivered earnings and revenue surprises of 66.67% and 1.87%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Molson Coors' (TAP) Strategies Outrun Inflation Woes in Q2?
by Zacks Equity Research
Molson Coors' (TAP) strategic investments and premiumization efforts drive robust growth amid industry challenges and inflationary pressures. Let us see how the Q2 performance is likely to have been.
Medifast (MED) Q2 Earnings in the Cards: Factors to Watch
by Zacks Equity Research
Medifast's (MED) Q2 results are likely to reflect customer acquisition challenges stemming from the growth of GLP-1 medications in markets.
Pilgrim's Pride (PPC) Q2 Earnings Top Estimates, Sales Up Y/Y
by Zacks Equity Research
Pilgrim's Pride's (PPC) second-quarter results reflect earnings and sales growth due to portfolio diversification strategies, operational excellence, branded offerings and key customer partnerships.
US Foods (USFD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
US Foods (USFD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mondelez (MDLZ) Q2 Earnings Beat, Organic Revenues Up 2.5%
by Zacks Equity Research
Mondelez (MDLZ) posts soft sales in second-quarter 2024, whereas organic revenues grow 2.5%. Strong pricing and cost management actions also fuel bottom-line growth.
Is BRF (BRFS) Stock Outpacing Its Consumer Staples Peers This Year?
by Zacks Equity Research
Here is how BRF (BRFS) and Freshpet (FRPT) have performed compared to their sector so far this year.
Kraft Heinz (KHC) Tops Q2 Earnings Estimates
by Zacks Equity Research
Kraft Heinz (KHC) delivered earnings and revenue surprises of 6.85% and 0.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Freshpet (FRPT) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Freshpet (FRPT) reachead $118.52 at the closing of the latest trading day, reflecting a -1.61% change compared to its last close.
Archer Daniels (ADM) Q2 Earnings & Revenues Miss, Down Y/Y
by Zacks Equity Research
Archer Daniels (ADM) reports lower revenues year over year in second-quarter 2024 owing to a decline in sales across its segments.
Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Can Clorox's (CLX) Pricing & Cost-Saving Plan Aid Q4 Earnings?
by Zacks Equity Research
Clorox's (CLX) Q4 results are expected to reflect gains from pricing strategies and cost-saving initiatives, as well as progress on the IGNITE strategy, amid high SG&A expenses.
Freshpet (FRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Freshpet (FRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Take the Zacks Approach to Beat the Markets: Chewy, Pitney Bowes, 3M in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Newell's (NWL) Q2 Earnings Beat Mark, Soft Core Sales Hurt
by Zacks Equity Research
Newell (NWL) reports a sales decline in second-quarter 2024, owing to a core sales drop of 4.2% year over year.
Colgate (CL) Stock Gains on Q2 Earnings Beat, '24 EPS View Hike
by Zacks Equity Research
Colgate's (CL) Q2 results reflect continued gains in volume and pricing, offset by greater negative impacts of currency, leading to robust organic sales growth. CL raises the adjusted EPS view for 2024.